News AZ grabs pair of EU approvals for top cancer drugs AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.
News BeiGene abandons TIGIT antibody after lung cancer flop BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.
News First drug backed for NHS use in untreated Hodgkin lymphoma Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated late-stage Hodgkin lymphoma.
News CARGO offloads staff after abandoning lead CAR-T Less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff.
News Roche taps Oxford BioTherapeutics for cancer drug discovery Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.
News Sofinnova closes new fund and backs a trio of new biotechs Sofinnova Partners has raised €165m for its new biotech fund and backed three startups working on Alzheimer's, fibrotic diseases, and cell therapies.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.